JP2020523342A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523342A5 JP2020523342A5 JP2019568236A JP2019568236A JP2020523342A5 JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5 JP 2019568236 A JP2019568236 A JP 2019568236A JP 2019568236 A JP2019568236 A JP 2019568236A JP 2020523342 A5 JP2020523342 A5 JP 2020523342A5
- Authority
- JP
- Japan
- Prior art keywords
- weight
- composition
- mass
- baicalein
- oroxylin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RTIXKCRFFJGDFG-UHFFFAOYSA-N chrysin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 RTIXKCRFFJGDFG-UHFFFAOYSA-N 0.000 description 18
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 18
- 239000000203 mixture Substances 0.000 description 10
- NYCXYKOXLNBYID-UHFFFAOYSA-N 5,7-Dihydroxychromone Natural products O1C=CC(=O)C=2C1=CC(O)=CC=2O NYCXYKOXLNBYID-UHFFFAOYSA-N 0.000 description 9
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 9
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 9
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 9
- 229940015301 baicalein Drugs 0.000 description 9
- 229940043370 chrysin Drugs 0.000 description 9
- 235000015838 chrysin Nutrition 0.000 description 9
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 8
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 8
- 230000000694 effects Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 2
- 208000024667 ABeta amyloidosis, Dutch type Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000036536 dutch type ABeta amyloidosis Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- -1 gummy Substances 0.000 description 1
- 208000027061 mild cognitive impairment Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762520141P | 2017-06-15 | 2017-06-15 | |
| US62/520,141 | 2017-06-15 | ||
| PCT/US2018/037454 WO2018232063A1 (en) | 2017-06-15 | 2018-06-14 | Compositions and methods for beta secretase inhibition |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523342A JP2020523342A (ja) | 2020-08-06 |
| JP2020523342A5 true JP2020523342A5 (enExample) | 2021-07-26 |
| JP7209645B2 JP7209645B2 (ja) | 2023-01-20 |
Family
ID=64655980
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568236A Active JP7209645B2 (ja) | 2017-06-15 | 2018-06-14 | βセクレターゼの阻害のための組成物および方法 |
| JP2019569247A Active JP6796217B2 (ja) | 2017-06-15 | 2018-06-15 | 神経保護組成物とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019569247A Active JP6796217B2 (ja) | 2017-06-15 | 2018-06-15 | 神経保護組成物とその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11458117B2 (enExample) |
| EP (2) | EP3638277B1 (enExample) |
| JP (2) | JP7209645B2 (enExample) |
| KR (2) | KR20190134809A (enExample) |
| CA (2) | CA3063751C (enExample) |
| ES (1) | ES3005508T3 (enExample) |
| FI (1) | FI3638277T3 (enExample) |
| PL (2) | PL3638277T3 (enExample) |
| WO (2) | WO2018232063A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018232063A1 (en) * | 2017-06-15 | 2018-12-20 | Muhammed Majeed | Compositions and methods for beta secretase inhibition |
| US12465585B2 (en) * | 2018-06-15 | 2025-11-11 | Sami-Sabinsa Group Limited | Compositions for the management of seizure induced neurotoxicity |
| CN110115712A (zh) * | 2019-07-04 | 2019-08-13 | 兰州大学 | 一种同时激活氧化磷酸化通路和抑制糖酵解途径的激活剂及其应用 |
| KR20220049575A (ko) * | 2019-08-26 | 2022-04-21 | 새미-사빈사 그룹 리미티드 | 식물 활성물질 및 이의 오염 방지 효과 |
| CN114246879B (zh) * | 2021-12-30 | 2023-10-27 | 沈阳兴齐眼药股份有限公司 | 木蝴蝶苷b在制备用于预防、控制和/或治疗眼部疾病药物中的用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8034387B2 (en) * | 2002-04-30 | 2011-10-11 | Unigen, Inc. | Formulation of a mixture of free-B-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| WO2003092599A2 (en) * | 2002-04-30 | 2003-11-13 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans as a therapeutic agent |
| US8945518B2 (en) * | 2002-04-30 | 2015-02-03 | Unigen, Inc. | Formulation of dual eicosanoid system and cytokine system inhibitors for use in the prevention and treatment of oral diseases and conditions |
| WO2005020932A2 (en) * | 2003-09-02 | 2005-03-10 | Unigen Pharmaceuticals, Inc. | Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments |
| JP2009527461A (ja) * | 2006-01-09 | 2009-07-30 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 胃腸毒性、関連する症状及び潰瘍の処置のための天然作用物質 |
| WO2007096739A2 (en) * | 2006-02-21 | 2007-08-30 | Council Of Scientific And Industrial Research | Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof |
| EP2007385A4 (en) | 2006-03-23 | 2010-08-18 | Sinai School Medicine | CARDIOVASCULAR COMPOSITION AND ITS USE FOR THE TREATMENT OF MORBUS ALZHEIMER |
| KR20080008929A (ko) * | 2006-11-20 | 2008-01-24 | 대한민국(관리부서 식품의약품 안전청장) | 오록실린 ａ를 함유하는 인지 기능 장애 관련 질환의 예방및 개선용 건강기능식품 |
| BR112015004418A2 (pt) * | 2012-08-29 | 2017-07-04 | Mannkind Corp | composição de pó seco inalável, sistema de liberação de fármaco, processo para formar uma partícula e kit. |
| WO2018089325A1 (en) * | 2016-11-11 | 2018-05-17 | Muhammed Majeed | Composition containing oroxylin a and method of extraction thereof |
| WO2018232063A1 (en) | 2017-06-15 | 2018-12-20 | Muhammed Majeed | Compositions and methods for beta secretase inhibition |
-
2018
- 2018-06-14 WO PCT/US2018/037454 patent/WO2018232063A1/en not_active Ceased
- 2018-06-14 KR KR1020197034396A patent/KR20190134809A/ko not_active Ceased
- 2018-06-14 ES ES18816475T patent/ES3005508T3/es active Active
- 2018-06-14 EP EP18816475.0A patent/EP3638277B1/en active Active
- 2018-06-14 FI FIEP18816475.0T patent/FI3638277T3/fi active
- 2018-06-14 US US16/008,219 patent/US11458117B2/en active Active
- 2018-06-14 JP JP2019568236A patent/JP7209645B2/ja active Active
- 2018-06-14 CA CA3063751A patent/CA3063751C/en active Active
- 2018-06-14 PL PL18816475.0T patent/PL3638277T3/pl unknown
- 2018-06-15 EP EP18817403.1A patent/EP3638278B1/en active Active
- 2018-06-15 US US16/009,490 patent/US10894029B2/en active Active
- 2018-06-15 JP JP2019569247A patent/JP6796217B2/ja active Active
- 2018-06-15 CA CA3063757A patent/CA3063757C/en active Active
- 2018-06-15 PL PL18817403.1T patent/PL3638278T3/pl unknown
- 2018-06-15 WO PCT/US2018/037724 patent/WO2018232224A1/en not_active Ceased
- 2018-06-15 KR KR1020197033007A patent/KR20190131589A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523342A5 (enExample) | ||
| US20240350453A1 (en) | Methods of treating neurological and psychiatric disorders | |
| P Cardinali et al. | Clinical aspects of melatonin intervention in Alzheimer's disease progression | |
| JP2003524613A5 (enExample) | ||
| MXPA04011762A (es) | Una combinacion de antagonista de nmda e inhibidores de acetilcolinesterasa para el tratamiento de la enfermedad de alzheimer. | |
| WO2020222799A1 (en) | A method of treating mental, behavioral, cognitive disorders | |
| FI3638277T3 (fi) | Koostumukset ja menetelmät beetasekretaasin estämiseksi | |
| JP2022531003A (ja) | 結節性硬化症複合体の治療におけるカンナビジオールの使用 | |
| MX2008000250A (es) | Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y | |
| CZ355897A3 (cs) | Způsob léčení mánie a bipolárních poruch | |
| US20180200259A1 (en) | GALANTAMINE CLEARANCE OF AMYLOID ß | |
| JP4880223B2 (ja) | スクシネートエステル誘導体の痴呆症の治療への使用 | |
| CN114870018A (zh) | 炎症小体nlrp3抑制剂通过抑制神经系统炎症在制备治疗阿尔茨海默症药物中的应用 | |
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| KR20200065012A (ko) | 글리신 뇌병증 치료를 위한 벤조에이트 함유 조성물의 사용 | |
| JP2020502106A (ja) | 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 | |
| JP7295145B2 (ja) | 神経変性疾患を治療するための医薬及びその使用 | |
| KR20060128961A (ko) | 중추신경계 질환 또는 질병의 치료 및 관리를 위해탈리도미드를 사용하는 방법 및 조성물 | |
| KR20210113240A (ko) | 신경 변성 질환의 예방 또는 치료약 | |
| DE69808607T2 (de) | Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz | |
| JP6465592B2 (ja) | 涙液分泌促進組成物 | |
| CN111617255B (zh) | 用于治疗中枢神经系统紊乱的组合疗法 | |
| KR102390613B1 (ko) | 항암제 화합물을 유효성분으로 포함하는 알츠하이머성 치매의 예방 또는 치료용 조성물 | |
| CN112569217B (zh) | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 | |
| WO2025143100A1 (ja) | 神経変性疾患治療剤 |